314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.

Episode metadata supplied by the publisher feed · Published Jul 18, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

0:00 33:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 33 minutes long.

When was this The Readout Loud episode published?

This episode was published on July 18, 2024.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!